Hologic Analysts Boost Their Forecasts After Q3 Results

Hologic, Inc. HOLX reported upbeat earnings for its third quarter, but issued soft guidance on Monday.

Hologic reported quarterly earnings of $1.06 per share which beat the analyst consensus estimate of $1.02 per share. The company reported quarterly sales of $1.011 billion which beat the analyst consensus estimate of $1.000 billion, according to data from Benzinga Pro.

“In our third quarter of fiscal 2024, Hologic returns to top-line reported growth and once again exceeded the high-end of our guidance for both the top and bottom-line,” said Stephen P. MacMillan, the Company’s Chairman, President and Chief Executive Officer. “Our strong fiscal quarter and year-to-date results continue to highlight the durable strength across our broad portfolio, with our Diagnostics (ex-COVID), Breast Health, and Surgical franchises delivering at or above our expectations. We are excited to finish fiscal 2024 strong as we continue to build for the long term.”

Hologic said it sees fourth-quarter adjusted earnings of 97 cents to $1.04 per share, versus market estimates of $1.04 per share. The company projects FY24 adjusted earnings of $4.04 to $4.11 per share, versus estimates of $4.07 per share.

Hologic shares gained 1.3% to close at $79.64 on Monday.

These analysts made changes to their price targets on Hologic following the announcement.

• JP Morgan analyst Casey Woodring maintained Hologic with an Overweight rating, while raising the price target from $91 to $95.
• RBC Capital analyst Conor McNamara maintained the stock with a Sector Perform rating and boosted the price target from $81 to $82.
• Needham analyst Mike Matson, meanwhile, reiterated Hologic with a Buy rating and maintained a $90 price target.

Read More:

• US Stocks Close Mixed Ahead Of Big Earnings, Fed Decision: Investor Optimism Improves Further